Revelation Biosciences Files 8-K
Ticker: REVBW · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $579,600 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
REVELATION BIOSCIENCES FILED AN 8-K ON 10/15/25 - REG FD & FINANCIALS.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on October 15, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Petra Acquisition Inc. until April 23, 2020, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides an update on the company's regulatory disclosures and financial reporting, which is crucial for investors to stay informed about its current status.
Risk Assessment
Risk Level: low — This is a routine filing for current reports and financial statements, not indicating any immediate adverse events.
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- Petra Acquisition Inc. (company) — Former company name
- October 15, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to include financial statements and exhibits.
When was Revelation Biosciences, Inc. formerly known as Petra Acquisition Inc.?
Revelation Biosciences, Inc. was formerly known as Petra Acquisition Inc. until April 23, 2020.
In which state is Revelation Biosciences, Inc. incorporated?
Revelation Biosciences, Inc. is incorporated in Delaware.
What is the business address of Revelation Biosciences, Inc.?
The business address of Revelation Biosciences, Inc. is 4660 La Jolla Village Drive, Suite 100, San Diego, California, 92122.
What is the SIC code for Revelation Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Revelation Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-15 17:06:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $579,600 — of common stock at an exercise price of $579,600 per share REVBW The Nasdaq Stock Ma
Filing Documents
- revb-20251015.htm (8-K) — 51KB
- revb-ex99_1.htm (EX-99.1) — 17KB
- img220778470_0.jpg (GRAPHIC) — 18KB
- 0001193125-25-240400.txt ( ) — 236KB
- revb-20251015.xsd (EX-101.SCH) — 47KB
- revb-20251015_htm.xml (XML) — 7KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure . On October 15, 2025, Revelation Biosciences, Inc. (the "Company") issued a press release that its Special Meeting of Stockholders held on October 15, 2025 was adjourned until October 29, 2025 because a quorum was not present. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1 attached hereto, shall be deemed "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 15, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: September 15, 2025 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)